Financial Management Professionals Inc. Purchases 2,000 Shares of Pfizer Inc. (NYSE:PFE)

Financial Management Professionals Inc. raised its position in Pfizer Inc. (NYSE:PFE) by 11.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,089 shares of the biopharmaceutical company’s stock after purchasing an additional 2,000 shares during the period. Financial Management Professionals Inc.’s holdings in Pfizer were worth $530,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of PFE. GoalVest Advisory LLC lifted its holdings in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the last quarter. Creekmur Asset Management LLC bought a new stake in shares of Pfizer during the 4th quarter worth $32,000. VisionPoint Advisory Group LLC lifted its holdings in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the last quarter. Tennessee Valley Asset Management Partners bought a new stake in shares of Pfizer during the 4th quarter worth $36,000. Finally, DiNuzzo Private Wealth Inc. bought a new stake in shares of Pfizer during the 4th quarter worth $37,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 0.7 %

Shares of NYSE PFE opened at $27.99 on Friday. The firm’s 50 day moving average price is $27.90 and its 200-day moving average price is $27.69. The company has a market cap of $158.61 billion, a PE ratio of -466.42, a P/E/G ratio of 1.09 and a beta of 0.70. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $37.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s revenue was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.23 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.00%. The ex-dividend date is Thursday, July 25th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analysts Set New Price Targets

PFE has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley boosted their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $35.86.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.